Buy Array BioPharma (ARRY) On Weakness Surrounding Triplet Data - Stifel
Tweet Send to a Friend
Stifel analyst Stephen Willey reiterated a Buy rating and $29.00 price target on Array BioPharma (NASDAQ: ARRY) after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
